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ABSTRACT
We sought to determine whether patients with hematologic malignancies treated by nonmyeloablative hemato-
poietic cell transplantation (HCT) at a single institution between December 1997 and June 2006 had worse
outcomes with grafts from unrelated donors (URDs) (n 5 184) compared with HLA-identical related donors
(n 5 221). The nonmyeloablative preparative regimen consisted of 2 Gy of total body irradiation (TBI) with
(78%) or without (22%) fludarabine, along with posttransplantation mycophenolate mofetil (MMF) and cyclo-
sporine (CSa). After adjusting for the HCT comorbidity index, relapse risk, patient age, stem cell source, pre-
parative regimen, previous cytomegalovirus (CMV) infection, and sex mismatch of donor and recipient in
multivariate analysis, we found no statistically significant differences between unrelated and related HCT recip-
ients in terms of risk of nonrelapse mortality (NRM; hazard ratio [HR] 5 0.98; 95% confidence interval 5 0.6-
1.6; P 5 .94), relapse (HR 5 1.04; 95% confidence interval 5 0.7-1.5; P 5 .82), or overall mortality (HR 5 0.99;
95% confidence interval5 0.7-1.4; P5 .94).Overall rates of severe acute and extensive chronic graft-versus-host
disease (aGVHD, cGVHD) also were not significantly different between the 2 groups. We conclude that within
the limitations of a retrospective study, these results indicate that candidates for nonmyeloablativeHCTwithout
suitable related donors may expect similar outcomes with grafts from URDs.
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Most patients with hematologic malignancies who
might benefit from treatment by allogeneic hemato-
poietic cell transplantation (HCT) lack HLA-identical
related donors (MRDs) [1]. For these patients, unre-
lated volunteers (URDs) are being increasingly used
as donors. Historically, HCT from URDs after condi-
tioning with myeloablative preparative regimens has
been associated with increased risk of nonrelapse mor-
tality (NRM) and, consequently, decreased overall sur-
vival (OS) compared with results for MRDs [2-6].
These differences have been attributed primarily to
the greater degree of genetic disparity betweenURD–recipient pairs compared with related pairs.
With the advent of high-resolution HLA typing and
the resulting improved matching between URDs and
their recipients, outcomes after URD transplantation
have improved [7-10]. This improvement has been as-
cribed to decreased rates of graft-versus-host disease
(GVHD) and accelerated immune reconstitution
[11]. Even with high-resolution HLA typing, URD–
recipient pairs may have greater disparity for numer-
ous minor histocompatibility antigens compared with
related pairs, which may contribute to the persistently
higher rates of GVHD and, consequently, NRM after
HCT from URDs compared with MRDs [12].
1500 M. Mielcarek et al.In nonmyeloablative HCT, graft-versus-tumor
(GVT) effects have replaced high-dose cytotoxic ther-
apy as the conceptual basis for treating underlying ma-
lignancies [13-17]. The use of potent pregrafting and
postgrafting immunosuppression has allowed a major
reduction in pretransplantation cytotoxic therapy
without compromising engraftment of hematopoietic
donor cells. The use of nonmyeloablative conditioning
avoids major regimen-related toxicities, making it pos-
sible to treat older and medically infirm patients who
are at greater risk for complications after treatment
with conventional transplantation regimens [13,16,
18,19]. The immunobiology of nonmyeloablative
HCT differs from that of myeloablative HCT in sev-
eral important aspects. Compared with myeloablative
HCT, nonmyeloablative HCT is associated with (a)
decreased release of inflammatory cytokines resulting
from limited tissue damage during administration of
the conditioning regimen [20-24], (b) a transient and
potentially tolerogenic state of mixed donor/host chi-
merism [25,26], and (c) the use of novel regimens for
immunosuppression after HCT [13,14,27,28]. These
differences might account for the lower rates of severe
GVHD after unrelated HCT with nonmyeloablative
conditioning compared with myeloablative condition-
ing [29-31].
In this retrospective study, we investigated
whether outcomes in patients who underwent HCT
with nonmyeloablative conditioning also differed
according to donor type. After adjusting for factors
known to influence outcome after allografting in mul-
tivariate analysis, we found that the use of URDs did
not appear to increase either NRMor overall mortality
after HCT with nonmyeloablative conditioning.
PATIENTS AND METHODS
Eligibility Criteria
Patients who underwent nonmyeloablative HCT
from MRDs or URDs for treatment of hematologic
malignancies at the Fred Hutchinson Cancer Research
Center between December 1997 and June 2006 were
screened for study eligibility. The patients had signed
forms approved by the Institutional Review Board
documenting informed consent to participate in the
clinical trials and to allow the use of protected health
information for research. To be included in the analy-
sis, all related donors were HLA-matched siblings
based on family studies [8].
Sequence-specific oligonucleotide hybridization
and/or sequencing-based typing methods were used
to define exons 2 and 3 of HLA-A, B, and C alleles
and exon 2 of DRB1 and DQB1 alleles in all donor–
recipient pairs. Unrelated pairs were defined as
matched if donors and recipients had identical probe
hybridization patterns. The 82 DQB1*03 and 06-
positive donor–recipient pairs with identical exon 2oligonucleotide probe patterns potentially representing
2 different DQB1*0302, 0303, 0602, or 0603 alleles
(1 frequent and the other very rare) were considered to
bematched.The analysis included 405 patientswith fol-
low-up as of January 2007. Of these 405 patients, 184
patients had URDs (45%) and 221 had MRDs (55%).
Preparative Regimens, Hematopoietic Cell
Sources, and Supportive Care
Patients received low-dose total body irradiation
(TBI; 2 Gy) alone (22%) or in combination with
fludarabine (30 mg/m2 body surface area/day, for 3
consecutive days) (78%) [13,27]. Most recipients
(98%) were given granulocyte colony-stimulating fac-
tor (G-CSF)-mobilized peripheral bloodmononuclear
cells (G-PBMCs); 2% were given bone marrow grafts.
Antimicrobial and cytomegalovirus (CMV) prophy-
laxis and blood product support were administered as
described previously [30].
Prophylaxis Against GVHD
Postgrafting immunosuppression included myco-
phenolate mofetil (MMF) and cyclosporine (CSP) as
described previously [13,27]. Fifty unrelated recipients
(27%) received MMF 15 mg/kg every 12 hours, and
134 (73%) received MMF 15 mg/kg every 8 hours
[32]. Grading and treatment of GVHD were done as
described previously [30].
Categorization of Patients According to Their
Predicted Risks of NRM and Recurrent Malignancy
Outcomes with unrelated versus related grafts
were also compared in subgroups of patients according
to their predicted risks of NRM and recurrent malig-
nancy after HCT. Patients were grouped according
to HCT comorbidity indices (CIs) assigned at the
time of transplantation (scores 0, 1-2, and $ 3), which
serve as strong predictors for NRM [18,33,34], and
their estimated rates of recurrent malignancy per
year [35]. In brief, the risks of recurrent malignancy
were categorized as follows:
 Low (relapse rate per patient year, 0.0-0.25): chronic
lymphocytic leukemia (CLL) in remission, multiple
myeloma (MM) in remission, high-grade non-
Hodgkin lymphoma (NHL) in remission, low-grade
NHL or mantle cell lymphoma regardless of remis-
sion status, acute lymphoblastic leukemia (ALL) in
first remission, Waldenstro¨m’s macroglobulinemia,
or myelofibrosis
 Intermediate (relapse rate per patient year, 0.26-
0.50): CLL and MM without remission, acute mye-
logenous leukemia (AML) in remission, chronic my-
elogenous leukemia (CML) in first chronic phase, or
early-stage myelodysplastic syndromes (MDS)
 High (relapse rate per patient year, .0.50): High-
grade NHL without remission, Hodgkin disease,
Donor Type and Outcome after Nonmyeloablative Transplantation 1501ALL beyond first remission, AML without remis-
sion, CML beyond first chronic phase, or secondary
or advanced MDS
Statistical Analysis
Survival curves were estimated by the Kaplan-
Meier method. Cumulative incidence curves were esti-
mated as described previously [36]. Hazard ratios for
each endpoint were estimated from Cox regression
models, with NRM and relapse treated as competing
risks for analysis of these endpoints. Multivariate anal-
yses were adjusted for relapse risk category, HCT CI,
patient age, patient/donor sex mismatch, previous
CMV infection, and stem cell source. Every patient
with aURD received a conditioning regimen of fludar-
abine and low-dose TBI, whereas some patients with
MRDs received low-dose TBI alone. Therefore, anal-
yses were also adjusted for the absence of fludarabine
in the conditioning regimen. Modifying effects of co-
morbidity and relapse risk were evaluated by interac-
tion terms for donor relation with HCT CI (0 vs 1-2
vs $ 3) or relapse risk (low vs intermediate vs high).
All P values were based on Wald statistics derived
from hazard ratio (HR) analyses and were 2-sided. Ad-
justed survival curves were estimated based on
methods derived from Makuch et al. [37]; in brief,
the adjusted survival curve for the group of patients
with URDs represents a model-based estimate of sur-
vival for a group of patients having the baseline hazard
function estimated for patients with URDs, but with
the covariate characteristics of the group of patients
with MRDs. These estimates were derived from Cox
regression models stratified on donor relation, with
other adjustment factors incorporated as covariates.
Curves were estimated for each set of covariates from
the related donor group and then averaged to yield
the adjusted survival curve.
RESULTS
Patient Characteristics
Details regarding patient characteristics are listed
in Table 1. The median patient age was 54.5 years
(range, 20-72 years) for patients with MRDs and
55.9 years (range, 5-75 years) for those with URDs.
The distributions across HCT CI and relapse risk cat-
egories were similar in the 2 groups. Among the URD
transplants, 13% of donor–recipient pairs were mis-
matched for a single HLA-A, -B or -C allele. All pa-
tients with URDs were prepared with 2 Gy TBI and
fludarabine, whereas 40% of those with MRDs were
prepared with TBI alone. The median follow-up
time among surviving patients was 36.6 months (range,
3.3-98.7 months) for those receiving MRDs and 28.1
months (range, 2.6-71.8 months) for those receiving
URDs.HCT CI and Relapse Risk Categories
HCT CI categories separated patients into groups
with different risks of NRM (9%, 14%, and 29% at 2
years for HCT CI scores of 0, 1-2, and $ 3, respec-
tively), whereas the risk of recurrent malignancy did
not correlate with HCT CI (36%, 38% and 41% at
2 years for low, intermediate, and high risk, respec-
tively) (Table 2; Figure 1A and B). Conversely, the re-
lapse risk categories separated patients into groups
with different risks of recurrent malignancy (20%,
36%, and 56% at 2 years for low, intermediate, and
high risk, respectively), whereas the risk of NRM did
not correlate with these categories (24%, 15%, and






Median (range) 54.5 (20.4-72.7) 55.9 (5.1-74.6)
\ 50, n (%) 76 (34) 60 (33)
$ 50, n (%) 145 (66) 124 (67)
Diagnosis, n (%)
ALL 2 (1) 13 (7)
AML 29 (13) 50 (27)
MDS 26 (12) 22 (12)
CML 6 (3) 11 (6)
MM 61 (28) 19 (10)
NHL 46 (21) 33 (18)
Hodgkin disease 18 (8) 16 (9)
CLL 27 (12) 17 (9)
Other 6 (3) 3 (2)
Relapse risk category, n (%)
Low 46 (21) 42 (23)
Intermediate 111 (50) 83 (45)
High 64 (29) 59 (32)
HCT CI score, n (%)
0 65 (29) 40 (22)
1-2 69 (31) 57 (31)
31 87 (39) 87 (47)
Previous HCT, n (%)
Autologous 39 (18) 64 (35)
Allogeneic 5 (2) 5 (3)
Preparative regimen, n (%)
TBI 2 Gy 89 (40) 0
TBI 2 Gy 1 fludarabine 132 (60) 184 (100)
Stem cell source, n (%)
PBSCs 221 (100) 176 (96)
Bone marrow 0 8 (4)
Donor–recipient single
allele mismatch at
HLA-A, -B or -C, n (%)
No 221 (100) 160 (87)
Yes 0 24 (13)
Donor–recipient sex
mismatch, n (%)
No 105 (48) 103 (56)
Yes 116 (52) 81 (44)
Patient CMV serostatus, n (%)
Negative 96 (43) 84 (46)
Positive 125 (57) 100 (54)
PBSCs indicates peripheral blood stem cells.
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MRD 221 1.0 1.0 1.0
URD 184 1.01 (0.7-1.4) .95 0.98 (0.6-1.6) .93 1.10 (0.8-1.6) .60
Comorbidity category [34]
HCT CI 0 105 1.0 1.0 1.0
HCT CI 1-2 126 1.61 (1.0-2.5) 1.89 (0.9-3.9) 1.20 (0.8-1.8)
HCT CI $ 3 174 2.65 (1.8-4.0) \ .0001 3.93 (2.0-7.7) \ .0001 1.25 (0.8-1.9) .52
Relapse risk
category [35]
Low 88 1.0 1.0 1.0
Intermediate 194 1.31 (0.9-2.0) 0.76 (0.4-1.3) 1.82 (1.1-2.9)
High 123 2.94 (1.9-4.5) \ .0001 1.46 (0.8-2.5) .05 3.80 (2.3-6.2) \ .0001
Age at transplantation, years
\50 136 1.0 1.0 1.0
$50 239 1.38 (1.0-1.9) .04 1.61 (1.0-2.7) .06 1.04 (0.7-1.4) .83
Sex mismatch
No 208 1.0 1.0 1.0
Yes 197 1.39 (1.0-1.8) .02 1.64 (1.1-2.5) .03 1.29 (1.0-1.8) .10
Stem cell source
PBSCs 397 1.0 1.0 1.0
Bone marrow 8 1.36 (0.5-3.4) .53 0.96 (0.2-4.1) .96 1.86 (0.7-5.2) .28
Patient CMV status
Negative 180 1.0 1.0 1.0
Positive 225 1.23 (0.9-1.6) .16 1.71 (1.1-2.7) .02 1.19 (0.9-1.6) .29
Fludarabine in the preparative regimen
Yes 316 1.0 1.0 1.0
No 89 0.76 (0.5-1.2) .20 0.86 (0.4-1.6) .64 0.99 (0.6-1.5) .95
PBSCs indicates peripheral blood stem cells.23% at 2 years for HCT CI scores of 0, 1-2, and $ 3,
respectively) (Table 2; Figure 1C and D). Therefore,
these risk categorizations were applied in the analysis
of outcomes with unrelated versus related HCT.
NRM
The HRs of NRM for patients receiving URDs
versus those receiving MRDs showed no statistically
significant difference in univariate analysis (HR 1.22:
95% confidence interval5 0.8-1.9;P5 .36) (Figure 2A;
Table 3). This conclusion remained unchanged after
adjusting for HCTCI, relapse risk category, use of flu-
darabine in the preparative regimen, patient age, stem
cell source, previous CMV infection, and sexmismatch
of the donor and recipient in multivariate analysis
(HR 5 0.98; 95% confidence interval 5 0.6-1.6;
P 5 .94) (Figure 2A; Table 3). The hazard of NRM
for patients with URDs versus MRDs also showed
no statistically significant difference across HCT CI
subgroups (Table 3), although the statistical power
of this analysis was limited by the smaller numbers of
patients in these subgroups.
Recurrent Malignancy
The hazard of recurrent malignancy for patients
with URDs versus those withMRDs showed no statis-tically significant difference in univariate analysis
(HR 5 1.17; 95% confidence interval 5 0.9-1.6; P 5
.32) or multivariate analyses (HR 5 1.10; 95% confi-
dence interval, 0.8-1.6; P 5 .60) (Figure 2B; Table
3). There were also no statistically significant differ-
ences in the risk of relapse between recipients of
URDs versus those of MRDs across subgroups with
different risks of recurrent malignancy (Table 3).
Again, the statistical power of this analysis was limited
by the smaller numbers of patients in these subgroups.
Overall Mortality
The hazard of overall mortality for patients with
URDs versus those withMRDs showed no statistically
significant difference in univariate analysis (HR 5
1.29; 95% confidence interval 5 1.0-1.7; P 5 .08) or
multivariate analyses (HR5 1.01; 95% confidence in-
terval5 0.7-1.4; P5 .95) (Figure 2C; Table 3). There
were also no statistically significant differences in the
risk of overall mortality between recipients of URDs
versus those of MRDs across subgroups with different
HCT CI scores or risks of recurrent malignancy
(Table 3). Additional adjustment for presence of
single-allele mismatches at HLA class I between
URD donors and recipients did not change the results
(not shown).
Donor Type and Outcome after Nonmyeloablative Transplantation 1503Figure 1.Cumulative incidence of recurrent malignancy and NRM according to HCTCI and relapse risk categories. The
combined groups of patients with MRDs and URDs were categorized according to the presence of pretransplantation co-
morbidities (HCTCI: 0, 1-2, or$ 3) [18] (A, B) and the predicted risk of recurrent malignancy (low, intermediate, or high)
[35] (C, D). The cumulative incidence rates of recurrent malignancy (A, C) and NRM (B, D) are shown for respective
subgroups of patients.GVHD
Table 4 shows the distribution of patients with
aGVHD and cGVHD according to donor type.
Even though patients with URDs had a higher inci-
dence of grade II aGVHD compared with those with
MRDs (59% vs 37%; P \ .0001), the overall
incidence of grade III-IV aGVHD did not differ be-
tween the 2 groups (15% vs 15%). The overall
incidence of cGVHD requiring systemic immunosup-
pressive therapy was 67% after unrelated HCT and
68% after related HCT (P 5 .55). In Cox regression
analysis, the adjusted hazard of grade II–IV aGVHD
was higher in recipients of URDs compared with re-
cipients of MRDs (HR 5 1.93; 95% confidence inter-
val 5 1.5-2.5; P\ .0001), but the risks of developing
grade III–IV aGVHD (HR 5 1.03; 95% confidence
interval 5 0.8-1.4; P 5 .84) and cGVHD requiring
systemic immunosuppressive therapy (HR 5 1.21:
95% confidence interval5 0.9-1.6; P5 .15) were sim-
ilar in the 2 groups.DISCUSSION
The results of this retrospective analysis demon-
strate that compared with nonmyeloablative HCT
for hematologic malignancies from MRDs, transplan-
tation from URDs did not increase the risks of NRM
and overall mortality. In addition to factors known to
influence outcome after allogeneic HCT (including
patient age, stem cell source, type of preparative regi-
men, previous CMV infection, and sex mismatch of
donor and recipient), our overall analysis was also
adjusted for HCT CI (a powerful predictor of NRM)
[18,33,34] and for relapse risk categories [35]. Two dif-
ferent systems were used to categorize patients accord-
ing to their predicted risks of NRM [34] and recurrent
malignancy [35], because—in contrast to the experi-
ence with myeloablative HCT—a single categoriza-
tion system equally predictive for both outcomes
could not be defined for nonmyeloablative HCT.
Decades of experience with allogeneic myeloabla-
tive HCT has shown that transplantation from
1504 M. Mielcarek et al.URDs is associated with a greater risk of overall mor-
tality than HCT from MRDs [12,38-41]. The net
detrimental effect associated with unrelated grafts is
largelymediated by an increased risk ofGVHDand the
resulting increased risk of NRM, which typically is not
Figure 2.NRM, relapse or progression, and OS according to donor
type. Cumulative incidence of NRM (A) and relapse or progression
(B), and Kaplan-Meier survival estimates (C) in patients with HLA-
identical sibling donors (‘‘MRD,’’ n 5 221) compared with those
with URDs (‘‘URD,’’ n 5 184; P 5 .08). The third curve in each
panel (‘‘URD adjusted’’) shows the projected survival with URDs
after adjusting for HCT CI, relapse risk category, patient age,
stem cell source, previous CMV infection, and donor–recipient sex
mismatch.outweighed by themore potent immunologic effects of
unrelatedgrafts againstmalignant cells.With improved
HLA-typing technology and better matching between
URDs and their recipients, however, outcomes after
URD transplantation have improved substantially
[7], and—at least for certain patient groups—may
approach those observed with MRDs [42-46].
The similar risks of NRM and OS with unrelated
and related donors after nonmyeloablative condition-
ing found in our analysis could reflect the similar risks
of developing grade III-IV aGVHD (HR 5 1.03; P 5
.84). We speculate that despite the greater genetic dis-
parity between unrelated and related donor–recipient
pairs, decreased tissue damage and decreased release
of inflammatory cytokines, transient mixed donor–
host chimerism, or differences in the pharmacologic
immunosuppressive regimen associated with nonmye-
loablative HCT might have diminished the activation
and clonal expansion of cells that cause clinicalGVHD.
This conclusion was supported by results of earlier
studies demonstrating that the onset of GVHD
occurred later and the incidence was lower after HCT
with nonmyeloablative conditioning compared with
HCT with myeloablative conditioning [29-31].
The findings observed in our study population
might not apply to other populations treated with
possibly more toxic nonmyeloablative conditioning
regimens. It is conceivable that more severe gastroin-
testinal tissue damage or differences in postgrafting
immunosuppression associated with other nonmyeloa-
blative preparative regimens might translate into dif-
ferences in NRM that could affect OS.
Only 30% of patients with hematologic malignan-
cies who might benefit from treatment by HCT have
MRD. For older patients (particularly those over age
60 years), the availability of suitable sibling donors is
further limited by the concordant increased age of
their siblings. Even though older patients are typically
ineligible for myeloablative HCT, they often can be
considered for a nonmyeloablative transplantation ap-
proach. In this context, our findings of comparable
outcomes with MRDs and URDs in patients prepared
with our nonmyeloablative regimen are important,
because they suggest that in the absence of suitable
MRDs, well-matched URDs may offer a very reason-
able alternative that does not appear to be associated
with a detrimental outcome.
Retrospective designs have many limitations, in-
cluding the possibility of selection bias. In this study,
URDs were used only whenMRDs were not available,
and baseline characteristics of the 2 cohorts were sim-
ilar. Nonetheless, other types of bias could have been
present, but one ordinarily would expect any such
bias to have an unfavorable effect on outcomes among
patients with URDs. Despite the absence of statisti-
cally significant differences between outcomes for
patients with URDs versus those with MRDs in the
Donor Type and Outcome after Nonmyeloablative Transplantation 1505Table 3. Outcomes after transplantation from HLA-matched URDs compared with HLA-identical sibling donors*














Univariate 221 184 1.29 (1.0-1.7) .08 1.22 (0.8-1.9) .36 1.17 (0.9-1.6) .32
Multivariate* 221 184 1.01 (0.7-1.4) .95 0.98 (0.6-1.6) .93 1.10 (0.8-1.6) .60
Comorbidity
category [34]
HCT-CI 0 65 40 1.07 (0.5-2.3) 1.23 (0.3-4.4)
HCT-CI 1-2 69 157 1.28 (0.7-2.2) Trend† 1.03 (0.4-2.5) Trend†
HCT-CI $3 87 87 0.87 (0.6-1.3) .42 0.92 (0.5-1.7) .66
Relapse risk
category [35]
Low 46 42 1.22 (0.6-2.5) 0.49 (0.2-1.2)
Intermediate 111 83 1.07 (0.7-1.7) Trend† 0.85 (0.5-1.4) Trend†
High 64 59 0.91 (0.6-1.4) .47 1.76 (1.1-2.9) .007
Patient age
\50 years 76 60 1.10 (0.6-1.9) 0.65 (0.3-1.6) 1.70 (1.0-3.0)
$50 years 145 124 0.98 (0.7-1.4) .70 1.11 (0.7-1.9) .29 0.89 (0.6-1.4) .06
An HR . 1.0 indicates a more favorable outcome with related donors.
*Adjusted for patient age, HCTCI, relapse risk category, use of fludarabine in the preparative regimen, donor–recipient sex mismatch, stem cell
source, and previous CMV infection.
†Test for trend across comorbidity or relapse risk groups in the relative difference between URD and MRD outcomes.overall study population, it is possible that further
studies could identify specific subgroups in which un-
related grafts are disadvantageous.
In summary, except for an increased risk of mild
aGVHD, outcomes after HCT with nonmyeloablative
conditioning appear to be similar with HLA-matched
URDs andMRDs.We conclude that the lack of a suit-
able related donor should not pose an obstacle to con-
sidering HCT with nonmyeloablative conditioning
for patients with hematologic malignancies.
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